This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Immunoreactive trypsin (IRT)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Infants with cystic fibrosis 1 to 2 weeks of age show increased levels of immunoreactive trypsin in the plasma in the neonatal heel-prick test.

The test is positive if immunoreactive trypsin is greater than 80 mcg/litre. It is currently the best screening test for cystic fibrosis but cannot be done after the 8 weeks of life since the immunoreactive trypsin falls as pancreatic insufficiency develops.

Immunoreactive trypsin is also raised in haemorrhagic shock and encephalopathy.

Notes:

  • The National Screening Committee recommends that newborn blood spot screening include: Phenylketonuria (PKU), Congenital Hypothyroidism (CHT), Sickle Cell disorders, Cystic Fibrosis (CF) and Medium Chain Acyl Co-A Dehydrogenase Deficiency (MCADD)
  • Blood spot screening is offered to all babies up to one year of age, with the exception of CF where the test is valid up to 8 weeks of age only CF screening may detect some but not all carriers, SCD screening also detects carriers.

http://newbornbloodspot.screening.nhs.uk/


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.